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RPL23/uL14BRCA2 and CDKN1A(p21,CIP1)-interacting protein (BCCIP) is an evolutionary conserved protein
implicated in maintenance of genome stability and cell cycle progression. Two isoforms of BCCIP
with distinct C-terminal domains exist in humans. We show that mammalian BCCIPb, but not
BCCIPa, forms a ternary complex with the ribosomal protein RPL23/uL14 and the pre-60S trans-
acting factor eIF6. Complex formation is dependent on an intact C-terminal domain of BCCIPb.
Depletion of BCCIPb reduces the pool of free RPL23, and decreases eIF6 levels in nucleoli. Overex-
pression of BCCIPb leads to nucleoplasmic accumulation of extra-ribosomal RPL23 and stabilizes
overexpressed RPL23, suggesting that BCCIPb functions as nuclear chaperone for RPL23.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The protein BCCIP, also called TOK-1, has been originally identi-
ﬁed as an interaction partner of the tumor suppressor proteins
p21(CDKN1A,CIP1) and BRCA2 in yeast two-hybrid assays [1,2].
In humans, BCCIP exists in two isoforms, BCCIPa and BCCIPb,
which are generated by alternative pre-mRNA splicing of the 30
exon. While the N-terminal 258 amino acids are identical in both
isoforms, the C-terminal domains comprising 64 and 56 amino
acids in BCCIPa and BCCIPb, respectively, differ. Both BCCIPa and
BCCIPb are localized to the cell nucleus [1,2].
Overexpression and depletion studies in mouse and human cell
lines have implicated BCCIP in cell cycle control, i.e. G1/S transition
[3–5], homologous recombination and suppression of spontaneous
DNA damage [6,7]. The observed inﬂuence of BCCIP on the G1/S
checkpoint has been explained by its ability to regulate expression
of the CDK inhibitor p21 [3,4]. Whereas overexpression of BCCIPaand BCCIPb causes a G1/S delay accompanied by a p53-dependent
increase in p21 levels [3,4], downregulation of either isoform
reduces p21 levels and impairs checkpoint activation in response
to DNA damage [4].
Mouse knockdown experiments have recently demonstrated
that BCCIP is essential for embryonic development [8]. BCCIP-
deﬁcient mouse embryonic ﬁbroblasts display severe proliferation
defects accompanied by spontaneous chromatin bridges, and are
sensitized towards UV-induced DNA damage [8]. Consistent with
a role of BCCIP in the maintenance of genome stability, reduced
BCCIP expression has been observed in several cancer types [9–13].
BCCIP is evolutionary conserved in eukaryotes. The budding
yeast homolog of BCCIP, Bcp1, is also essential and has been impli-
cated in the biogenesis of 60S ribosomal subunits as well as in
nuclear export of the PI4P 5-kinase Mss4 [14,15].
In the course of characterizing trans-acting factors involved in
ribosome biogenesis in human cells, we found BCCIPb associated
with eukaryotic initiation factor 6 (eIF6) in tandem-afﬁnity puriﬁ-
cation (TAP) experiments. Using either BCCIPa or BCCIPb as TAP
bait, we identiﬁed a complex of RPL23(uL14) and eIF6 as a speciﬁc
interaction partner of BCCIPb. Further analysis revealed that
BCCIPb is required to maintain a nucleoplasmic, extra-ribosomal
pool of RPL23.
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2.1. Molecular cloning
For expression of TAP constructs in HEK293 cells, pcDNA5/FRT/
TO-derived vectors encoding for eIF6-StHA, HASt-BCCIPa, HASt-
BCCIPb and C-terminal truncations thereof were generated as
described previously [16]. For expression of GFP-BCCIPa and
GFP-BCCIPb fusion proteins, the pcDNA5/FRT/TO vector backbone
(Invitrogen) was modiﬁed by insertion of the GFP coding sequence.
The pcDNA3-derived FLAG-RPL23 expression vector CMV-FLAG-
L23 has been described [17]. For bacterial expression of zz-eIF6
full-length or DC, pET28 (Novagen) was modiﬁed by inserting
the coding sequence encoding the zz-tag [18], followed by inser-
tion of an eIF6 full-length or DC-encoding insert into the NdeI
and XhoI sites. Co-expression of RPL23-His6 and BCCIPbwas driven
from a pET-Duet vector (Novagen).
2.2. Antibodies
Antibodies against human RPL23, LSG1, PA2G4, eIF6 used for
Western blotting and BCCIP were raised in rabbits against puriﬁed,
recombinant His-tagged proteins. An antibody speciﬁcally
recognizing the BCCIPb isoform was raised in rabbits against a
C-terminal peptide of BCCIPb (C-PGDKMNEIMDKLKEYLSV). Other
antibodies have been described previously [16,19,20]. Anti-FLAG
was obtained from Sigma (F1804), anti-eIF6 (sc-390441) for immu-
noﬂuorescence and anti-MRTO4 (sc-81856) from Santa Cruz, and
anti-HA from Covance (MMS-101P). Secondary antibodies for
immunoﬂuorescence were purchased from Invitrogen (LuBio-
Science, Switzerland).
2.3. Tandem afﬁnity puriﬁcation and mass spectrometry
TAP was performed from stable HEK293 FlpIn TRex cells 24 h
after induction of expression of the indicated bait proteins with
0.5 lg/ml tetracycline as previously described [16]. The eluatesFig. 1. BCCIPb forms a complex with RPL23 and eIF6. (A) Tandem afﬁnity puriﬁcation
BCCIPa and BCCIPb. Eluates were analyzed by SDS–PAGE and silver staining. TAP bait p
indicated by an open circle. (B) Western blot analysis of the TAP eluates using the ind
expressed in E. coli. Bacterial lysates (input) were either used individually or mixed
associated factors by IMAC. Inputs and eluates were analyzed by SDS–PAGE followed bywere analyzed by SDS–PAGE followed by silver staining, Western
blotting or mass spectrometric analysis of selected protein bands
as described [16].
2.4. Protein expression and in vitro binding assays
Proteins were expressed in Escherichia coli Rosetta (Novagen) at
25 C. Cells were lysed in lysis buffer (10 mM Tris/HCl pH 7.5,
200 mM NaCl, 2 mM MgCl2, 5% glycerol, 50 mM imidazole, 2 mM
b-mercaptoethanol) by sonication. To promote complex formation,
the lysates were mixed and incubated at 4 C for 1 h. Then, Ni–NTA
agarose was added for 1 h. Beads were washed four times in lysis
buffer and bound proteins were eluted with 400 mM imidazole.
Eluates were analyzed by SDS–PAGE followed by Coomassie stain-
ing or Western blotting.2.5. Transient transfections, RNAi and immunoﬂuorescence
Cells were transiently transfected for 24 h using X-tremeGENE 9
(Roche) and ﬁxed in 4% PFA. For RNAi, cells were transfected with
9 nM siRNA using Interferin (Polyplus transfection) for 72 h and
either ﬁxed in 4% PFA or harvested for sucrose gradient centrifuga-
tion or Western blot analysis. The following siRNA were used: All-
Stars negative control siRNA (Qiagen); si-BCCIPa GAACCUUCAUG
ACUGUUGG; si-BCCIPb GAGGCAAAUGGUCUUUUGA [4]. Immuno-
ﬂuorescence analysis was performed as previously described
[20]. Images were taken using a Leica SP2 confocal scanning
system.
2.6. Sucrose gradient analysis
400 lg of HeLa cell extract were loaded onto linear 10–45%
sucrose gradients in 10 mM Tris/HCl pH 7.5, 100 mM KCl, 2 mM
MgCl2 and centrifuged for 2 h at 55000 rpm, 4 C in a TLS55 rotor
(Beckman Coulter). Gradient fractions were precipitated with
TCA and analyzed by Western blotting.was performed using cell lysates of HEK293 cells expressing tagged forms of eIF6,
roteins are marked with asterisks. Protein band examined by mass spectrometry is
icated antibodies. (C) zz-eIF6, zz-eIF6DC, BCCIPb, or BCCIPb and RPL23-His6 were
(zz-eIF6DC and BCCIPb/RPL23-His6 lysates) for retrieval of His-tagged RPL23 and
Coomassie blue staining.
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3.1. BCCIPb, RPL23 and eIF6 form a protein complex
To identify factors associated with human pre-60S particles, we
used the 60S ribosomal subunit biogenesis factor eIF6 [21,22] as
bait for TAP. eIF6 was expressed with a C-terminal tandem strepta-
vidin-binding peptide (St) and hemagglutinin epitope (HA) tag in
HEK293 cells using an experimental setup previously employed
for the puriﬁcation of pre-ribosomal particles [16,23]. Eluates of
eIF6-StHA TAP indeed contained pre-60S particles as indicated by
the complex pattern of silver stained bands in SDS–PAGE
(Fig. 1A, left lane), and as veriﬁed by the presence of known 60S
trans-acting factors like LSG1, NMD3, PA2G4/ARX1 and the ribo-
somal protein RPL10/uL16 on immunoblots (Fig. 1B, left lane).
However, the silver stained pattern of interacting partners revealed
that one protein of 45 kDa was present at a higher stoichiometry
than other proteins (Fig. 1A, left lane, open circle) and almost as
prominent as the bait (Fig. 1A, left lane, asterisks). The over-
enriched protein was identiﬁed as the b-isoform of BCCIP by massFig. 2. Overexpression of BCCIPb leads to nucleoplasmic accumulation of RPL23 and eIF6
BCCIPb. 24 h after transfection, cells were ﬁxed and analyzed for the localization of endog
by direct ﬂuorescence using confocal microscopy. Scale bar, 20 lm. (B) HASt-tagged full-
as TAP baits. TAP eluates were analyzed by SDS–PAGE followed by silver staining. (C) H
transiently expressed in HeLa cells. Protein localization was determined by indirect immspectrometry, which altogether identiﬁed 22 unique peptides and
covered almost the entire C-terminal domain of BCCIPb.
Reciprocal TAP with either N-terminally HASt-tagged BCCIPa or
BCCIPb as bait proteins conﬁrmed that only the b-isoform is part of
a protein complex consisting of three components, namely BCCIPb,
eIF6, and RPL23 (Fig. 1A, second and third lane). In contrast to eIF6
TAP, HASt-BCCIPb did not isolate a pre-ribosomal particle, indicat-
ing that BCCIPb might be either unable to associate with pre-
ribosomal subunits or that the interaction is too transient or
unstable (Fig. 1B). Notably, appending the TAP tag to the C termi-
nus of BCCIPb yielded a similar pattern of interaction partners
(data not shown).
Next, we tried to rebuild the trimeric complex using recombi-
nant proteins expressed in bacteria. Due to the low solubility of
both RPL23 and eIF6, we started with a dimer of untagged BCCIPb
and RPL23-His6. A complex of BCCIPb and RPL23-His6 could be suc-
cessfully isolated by immobilized metal afﬁnity chromatography
(IMAC) after co-expression of both factors from a bicistronic cas-
sette (Fig. 1C). There was no binding of BCCIPb to the Ni–NTA afﬁn-
ity matrix in the absence of RPL23-His6 (data not shown).. (A) HeLa cells were transiently transfected with constructs for GFP-BCCIPa or GFP-
enous RPL23, eIF6 or MRTO4 by indirect immunoﬂuorescence and of GFP-BCCIPa/b
length BCCIPb, BCCIPbDC3, or BCCIPbDC7 were expressed in HEK293 cells and used
ASt-tagged BCCIPb wild-type or the indicated C-terminal truncation variants were
unoﬂuorescence 24 h after transfection as in (A). Scale bar, 20 lm.
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to its N terminus and truncated the C-terminal 20 amino acids, as
these are likely unstructured [24]. IMAC experiments revealed that
zz-eIF6DC binds to the RPL23/BCCIPb dimer (Fig. 1C). We could
thus show that the three proteins are sufﬁcient to form the tri-
meric complex, without any additional factors or modiﬁcations
needed for complex formation. However, in the absence of
RPL23, binding of zz-eIF6DC to BCCIPb could not be reconstituted
in these in vitro binding studies (data not shown), which might
indicate that eIF6 associates with BCCIPb indirectly via RPL23. A
direct interaction between RPL23 and eIF6 has been previously
documented for both their archaeal (L14; IF6) and yeast homologs
(rpL23; Tif6) [25,26]. Currently, we cannot exclude that an interac-
tion between BCCIPb and eIF6 in the absence of RPL23 can exist in
principle. For instance, BCCIPb-eIF6 interaction might require an
intact C terminus of eIF6, certain posttranslational modiﬁcations
or a speciﬁc conﬁguration of these factors on pre-ribosomal
particles.
3.2. Overexpression of BCCIPb leads to nucleoplasmic accumulation of
RPL23
To investigate the functional importance of the observed
protein interactions, we next analyzed how overexpression andFig. 3. BCCIPb depletion results in a reduction of nucleolar eIF6. (A) HeLa cells wer
immunoﬂuorescence using the indicated antibodies. Scale bar, 20 lm. (B) Quantiﬁcation
(blue) signal was measured in 15 nucleoli per condition and normalized against control ce
(A) using the indicated antibodies.depletion of BCCIPb would affect the subcellular localization of
RPL23 and eIF6 in HeLa cells. Immunoﬂuorescence analysis of
control cells showed that RPL23 localized predominantly to the
cytoplasm as expected for a ribosomal protein, whereas the 60S
subunit biogenesis factor eIF6 was enriched in nucleoli.
Overexpression of BCCIPb, but not of BCCIPa, led to an accumu-
lation of RPL23 and eIF6 in the nucleoplasm (Fig. 2A). Localization
of MRTO4, another trans-acting factor involved in 60S subunit
biogenesis [23], was not affected by BCCIPb overexpression
(Fig. 2A). Western blot analysis did not reveal any major changes
in the levels of RPL23 or eIF6 upon overexpression of BCCIPb (data
not shown).
To analyze whether the observed effect of overexpression of
BCCIPb was dependent on the ability of BCCIPb to form a complex
with its two interaction partners, we set out to generate truncation
mutants of BCCIPb deﬁcient in RPL23 and eIF6 binding. Removal of
the three C-terminal amino acids of BCCIPb led to a reduced asso-
ciation with both RPL23 and eIF6, as revealed by TAP of HEK293
cell extracts expressing HASt-BCCIPbDC3 (Fig. 2B). Deletion of
the seven C-terminal amino acids strongly decreased complex
formation. Notably, the truncated bait proteins could be retrieved
in similar quantities as wild-type BCCIPb, indicating that the
overall stability of the bait protein was not compromised by the
truncations.e treated with the indicated siRNAs for 72 h. Cells were ﬁxed and analyzed by
of the experiment performed in (A). Nucleolar intensity of MRTO4 (black) or eIF6
lls. Bars are depicted with standard deviation. (C) Western blot analysis of cells from
Fig. 4. BCCIPb depletion destabilizes extra-ribosomal RPL23. HeLa cells were left untreated or depleted of either BCCIPa or BCCIPb by RNA interference. Cell extracts (inputs)
were fractionated on linear 10–45% sucrose gradients. Gradient fractions were precipitated and analyzed by SDS–PAGE followed by Western blotting using the indicated
antibodies.
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HeLa cells, they localized to the nucleus and were expressed at
similar levels as the wild-type protein. However, while overexpres-
sion of HASt-BCCIPbDC3 caused a slight nucleoplasmic accumula-
tion of RPL23, overexpression of HASt-BCCIPbDC7 did not (Fig. 2C).
This demonstrates that the effect of overexpression of BCCIPb on
the localization of RPL23 requires its ability to bind its partners.
The effect of BCCIPb overexpression on RPL23 was not altered
when eIF6 was co-overexpressed (data not shown), suggesting that
the phenotype is not due to limiting amounts of eIF6.
Depletion of BCCIPb caused a decrease in the nucleolar signal of
eIF6, accompanied by a slight decrease in eIF6 protein levels
(Fig. 3), further substantiating the link between BCCIPb and eIF6.
3.3. BCCIPb stabilizes a nuclear pool of extra-ribosomal RPL23
In our TAP experiments (Fig. 1), we had isolated HASt-BCCIPb in
a complex with eIF6 and RPL23 but had failed to detect any obvi-
ous association with pre-ribosomal particles. To analyze whether
endogenous BCCIPb might co-fractionate with precursors of 60S
subunits, we used sucrose gradient centrifugation of HeLa cell
extracts. Unlike the 60S trans-acting factors eIF6 or NMD3, which
partially co-sedimented with ribosomal proteins in the dense
fractions of the gradient (Fig. 4), both isoforms of BCCIP were only
detected in the lighter part of the gradient, where free proteins and
smaller protein complexes are found. We conclude that BCCIPb
might either be unable to associate with pre-60S particles or that
such interaction is too transient or unstable to be detected by
co-sedimentation or TAP.
Inspection of the sedimentation behavior of RPL23, however,
revealed that in contrast to other ribosomal proteins like RPL10/
uL16, RPS3/uS3, or RPL23A/uL23, an unusually large portion of
RPL23 was not associated with ribosomal subunits and migratedin the ‘free’ protein fractions of the sucrose gradient (Fig. 4 and
[20]). We therefore examined whether this extra-ribosomal pool
of RPL23 might be stabilized by presence of BCCIPb. Extracts of
HeLa cells depleted of either BCCIPa or BCCIPb by RNA interference
were fractionated by sucrose gradient centrifugation. The RPL23
content in the upper part of the gradient was unchanged after
depletion of BCCIPa. In contrast, depletion of BCCIPb almost com-
pletely eliminated RPL23 from the light part of the gradient,
whereas co-sedimentation of RPL23 with ribosomes was unaf-
fected (Fig. 4). Together, this suggests that BCCIPb might function
to stabilize a pool of RPL23 that is not incorporated into ribosomal
subunits.
If BCCIPb was an indispensable chaperoning factor for extra-
ribosomal RPL23, then the cellular concentration of BCCIPb should
determine howmuch extra-ribosomal RPL23 cells can maintain. To
test this model, we ﬁrst examined whether cellular BCCIPb levels
are sufﬁcient to allow for stabilization of over-expressed, extra-
ribosomal RPL23. We used an N-terminally FLAG-tagged variant
of RPL23 that has been previously employed as tool to study
extra-ribosomal functions of RPL23 (see below and [17,27]). Nota-
bly, FLAG-RPL23 could not be efﬁciently expressed in the absence
of additional BCCIPb (Fig. 5A, inputs). Upon co-expression of
HASt-BCCIPb, however, the levels of FLAG-RPL23 were consider-
ably higher. After sucrose gradient centrifugation, FLAG-RPL23
migrated at the top part of the gradient, like BCCIPb (Fig. 5A).
Analysis of FLAG-RPL23 at the singe cell level using immunoﬂu-
orescence conﬁrmed that the levels of BCCIPb limit FLAG-RPL23
expression. When transfected alone, FLAG-RPL23 was expressed
at low levels and localized to nucleoli (Fig. 5B, top left). Co-overex-
pression of BCCIPb, but not of BCCIPa, allowed for higher expres-
sion as evidenced by the strong ﬂuorescent signal obtained for
FLAG-RPL23 by immunoﬂuorescence. Under these conditions, both
GFP-BCCIPb and FLAG-RPL23 were majorly nucleoplasmic. Taken
Fig. 5. BCCIPb stabilizes extra-ribosomal RPL23 in the nucleus. (A) HeLa cells were left untreated or transiently transfected with constructs for expression of either FLAG-
RPL23 alone or together with HASt-BCCIPb. 24 h later, cell extracts were prepared (inputs), fractionated on a sucrose gradient and analyzed by SDS–PAGE followed by
Western blotting using the indicated antibodies. (B) Constructs for FLAG-RPL23 and GFP-BCCIPa or GFP-BCCIPb were transiently transfected into HeLa cells. After 24 h, cells
were ﬁxed and analyzed by indirect immunoﬂuorescence using an anti-FLAG antibody to detect exogenous FLAG-RPL23 and using direct ﬂuorescence for GFP-BCCIP or GFP-
BCCIPb. Pictures were taken by confocal microscopy at low and high exposure to account for the different expression levels. Scale bar, 20 lm.
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ization of extra-ribosomal RPL23 in the nucleus.
As BCCIPb forms a complex with nuclear RPL23 and eIF6, one
might speculate that BCCIPb functions as a chaperone for newly
synthesized RPL23, likely by preventing degradation of free
RPL23. BCCIPb might even promote incorporation of RPL23, per-
haps in a binary complex with eIF6, into nascent 60S subunits. If
so, then one would predict that BCCIPb is in turn required for
60S biogenesis. Although we have repeatedly tested this assump-
tion using 60S biogenesis reporters in different HeLa cell back-
grounds, there was no effect in the majority of experiments. This
could indicate that either the RPL23 chaperoning function of
BCCIPb is dispensable for 60S production or that its role is redun-
dant with other RPL23 chaperones such as nucleostemin [17] or
eIF6 itself. In support for a role of BCCIPb in 60S biogenesis comes
the observation that yeast bcp1ts cells display a strong nuclear 60S
subunit biogenesis defect [14]. It is currently unclear whether this
allele of BCP1 behaves as dominant-negative or loss-of-function.
Perhaps, a function of human BCCIPb in ribosome biogenesis onlymanifest in cells, such as primary cells, that do not overproduce
ribosomal constituents like many cancer cells do.
Alternatively, the function of BCCIPb as an RPL23 chaperone
might be required to control the activity of BCCIPb as a cell cycle
regulator, or to promote an extraribosomal function of RPL23 in
the nucleus. Based on the previous observations that BCCIP overex-
pression leads to p21-mediated cell cycle arrest that is dependent
on p53, and BCCIP depletion results in reduced p21 levels and a
failure to appropriately respond to DNA damage [3–5], our results
open the possibility that these effects involve a crosstalk with
RPL23 and/or eIF6. Clearly, the trimeric complex between BCCIPb,
RPL23 and eIF6 is ideally poised to constitute part of a relay mech-
anism between ribosome biogenesis and cell cycle control.
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